Effectiveness of binocularity-stimulating treatment in children with residual amblyopia following occlusion

Haeng-Jin Lee and Seong-Joon Kim

Abstract

Background: To evaluate the effectiveness of binocularity-stimulating treatment in children with residual amblyopia following occlusion therapy for more than 6 months.

Methods: Of patients with amblyopia caused by anisometropia and/or strabismus, patients with residual amblyopia following more than 6 months of occlusion therapy were included. Subjects underwent one of the following types of binocularity-stimulating therapy: Bangerter foil (BF), head-mounted display (HMD) game, or BF/HMD combination (BF + HMD). Factors including age, sex, types of amblyopia, visual acuity, and duration of treatment were investigated. Baseline and final (after at least 2 months of treatment) visual acuity were also compared.

Results: Twenty-two patients with a mean age of 8.7 ± 1.3 years were included. Seven patients had anisometropic amblyopia, 8 patients had strabismic amblyopia, and 7 patients had combined amblyopia. After 4.4 ± 1.8 months of treatment, logarithm of the minimum angle of resolution (logMAR) visual acuity in the amblyopic eye improved from 0.22 ± 0.20 to 0.18 ± 0.15. Five of 22 patients (22.7%) gained more than 0.2 logMAR, including 1 of 10 patients (10.0%) in the BF group, 2 of 7 patients (28.6%) in the HMD group, and 2 of 5 patients (40.0%) in the BF + HMD group. No significant differences in clinical characteristics were identified among the three groups.

Conclusions: Binocularity-stimulating therapy is somewhat beneficial in children with residual amblyopia and might be attempted when children no longer benefit from sufficient long-term period of occlusion therapy.

Keywords: Amblyopia, Residual amblyopia, Binocularity-stimulating treatment, Binocular treatment

Background

Most common treatments for amblyopia are monocular patching or penalization. By depriving the vision of sound eye, suppression of the amblyopic eye is eliminated and visual experience promote development or recovery of visual acuity of amblyopic eye. However, the response to patching usually reaches a plateau before vision in the amblyopic eye equals that of the sound eye [1–4], a condition referred to as residual amblyopia. Many amblyopes do not achieve a normal visual acuity, regardless of their patching compliance, and amblyopia often recurs after successful treatment in 25–50% of children [5–7]. In addition, older children and adults with amblyopia are rarely treated by conventional treatment.

Recent studies have reported that abnormal binocular interactions play a key role in amblyopia [8–13]. Binocularity-stimulating therapies on amblyopia using perceptual learning or dichoptic stimulus presentation have been introduced [9, 10, 14–16]. The mechanism of dichoptic presentation is presenting a strong stimulus to the amblyopic eye and a weak stimulus to the normal sound eye. Many devices can be used for dichoptic presentation: head-mounted display (HMD) [11], liquid crystal display (LCD) shutter glasses [17], 3-dimensional (3-D) shutter glasses [18, 19], and an iPad [20–23]. Researchers have shown that this type of therapy is effective in treating childhood amblyopia, especially binocular iPad games [20, 23, 24]. However, these studies mostly examined pediatric patients with recent amblyopia diagnoses, and the effect of...
binocularity-stimulation therapy on children with residual amblyopia (i.e., following patching and/or atropine therapy) has not yet been reported.

We previously developed a new software program which directly targets the binocular function using dichoptic presentation [25]. This program presents 3-D images in a virtual reality environment using a complete split screen view. The visual input to both eyes is controlled using an HMD. We evaluated the effectiveness of binocularity-stimulating treatment in children with residual amblyopia following occlusion therapy for more than 6 months using the HMD and Bangerter foil (BF).

Methods
Subjects
A medical chart review was performed on the prospectively collated subjects patients with amblyopia caused by strabismus and/or anisometropia between 2015 and 2016 at Seoul National University Hospital, South Korea. Patients with residual amblyopia following > 6 months occlusion therapy, who had good occlusion therapy compliance, and who underwent binocularity-stimulating treatment were included.

All patients underwent cycloplegic refraction at the first clinic visit to determine refractive error, which was converted to spherical equivalent values for statistical analysis (measured in diopters [D]). Myopia was defined as a negative spherical equivalent and hyperopia was defined as a positive spherical equivalent. Visual acuity was measured using a Snellen visual chart at every visit by one experienced examiner and was converted to the logarithm of the minimum angle of resolution (logMAR) for all data analyses. Ocular alignment was evaluated using the alternate prism cover test with accommodative targets for near (0.33 m) and distance (6 m) fixation. Stereaoacity was tested using the Titmus stereotest (Stereo Optical, Chicago, Illinois, USA). All values were transformed to log arcsec for the purpose of analysis.

Amblyopia was defined as an interocular difference of visual acuity between two eyes at least 0.2 LogMAR (2 lines). Types of amblyopia were divided as follows: anisometropic, strabismic, and combined. Anisometropic amblyopia was defined if there was a difference of at least 1.0D in spherical equivalent or 1.5D in astigmatism between the two eyes with no measurable strabismus. Strabismic amblyopia was defined as amblyopia in the presence of a heterotropia at distance and/or near fixation with a spherical equivalent interocular difference < 1.0D and < 1.5D interocular difference in astigmatism. The deviation is within 8 prism diopters with a history of strabismus surgery or resolution of misalignment after spectacle correction. Combined amblyopia was defined as amblyopia in the presence of both strabismus and anisometropia.

Patients with congenital or acquired ophthalmic conditions (e.g., optic nerve disease, glaucoma, media opacity, or cataract), systemic disease (e.g., neurologic disorders, developmental delays), or poor treatment compliance were excluded.

This study was approved by the Institutional Review Board of Seoul National University Hospital in South Korea and the study protocol followed the tenets of the Declaration of Helsinki. Written informed consent was obtained from the patients’ parents or guardians and patients more than 7 years.

Binocularity-stimulating treatment
Patients prospectively underwent one of three randomly chosen types of binocularity-stimulating treatment. We used the randomly generated numbers using computer program. One physician who unaware of this study generated the program and sealed sequentially numbered envelopes, which were concealed from investigators. After confirming eligibility and obtaining written informed consent, one of us (H- JL or S-JK) opened a sealed envelope, and assigned the patient to the appropriated treatment. These included BF, HMD games, and combination BF/HMD game therapy and binocularity-stimulating treatment was performed for at least 2 months.

Group 1 underwent BF with 0.6-, 0.4-, and 0.2-strength BF. The BF with a similar level to the amblyopic eye was chosen and the appropriate BF was applied on the glasses of the sound eye for 6 h a day. Group 2 underwent HMD game therapy using the “Ice Cream Truck” game on an HMD for 30 min a day. This game is a casual shooting game that requires players to throw ice cream to kids running towards them. The game is presented on a split screen, which allows independent control of 3-D image contrast and intensity using the 16-level Gaussian blur method. The amblyopic eye is presented images with increased contrast and intensity, while the sound eye is presented images with decreased contrast and intensity (Fig. 1). The player has the ability to select gameplay level as normal, expert, or hard. Group 3 underwent BF/HMD game combination therapy. Patients watched a video or played the 3-D game in a virtual reality environment using HMD for 30 min a day with BF on glasses of the sound eye.

Assessment of effectiveness of binocularity-stimulating treatment
Patient age, sex, amblyopia type, visual acuity, and treatment duration were investigated. At baseline and at each follow-up visit, best-corrected visual acuity was measured in each eye. After at least 2 months of binocularity-stimulating treatment, baseline and final visual acuity were compared. We also evaluated the number of patients with a vision improvement of 2 Snellen lines (0.2 logMAR) or more after binocularity-stimulating treatment.
Statistical analyses
The ANOVA test and Fisher’s exact test were performed using SPSS software (Version 16.0 for Windows; SPSS Science, Chicago, IL). For all tests, P-values < 0.05 were considered statistically significant. Continuous variables are reported as mean ± standard deviation.

Results

Demographic and clinical characteristics of subjects
Of total 22 patients (15 males) included, 10 patients were treated with BF, 7 patients were treated with HMD games, and 5 patients were treated with BF/HMD game combination therapy. The visual acuity at the initial visit was 0.73 ± 0.47 (range 0.2~1.8) LogMAR. Seven patients had anisometropic amblyopia, 8 patients had strabismic amblyopia, and 7 patients had combined amblyopia. The mean occlusion therapy duration was 2.5 ± 1.1 years (range: 0.7~4.7 years), and LogMAR visual acuity after occlusion was 0.22 ± 0.20 (range: 0.05~1.0). Occlusion therapy led to a visual gain of at least 0.2 LogMAR in 19 of 22 patients (86.4%). Mean age at the time of binocularity-stimulating treatment was 8.7 ± 1.3 years (range: 6.7~11.1 years) and mean duration of binocularity-stimulating was 4.4 ± 1.8 months (range: 2.1~8.1 months, Table 1).

Effect of binocularity-stimulating treatment on visual acuity
The visual acuity in amblyopic eye was changed from 0.22 ± 0.20 LogMAR to 0.18 ± 0.15 LogMAR after binocularity-stimulating treatment (P = 0.252). Of total 22 patients, there were no significantly different factors including sex, amblyopia type, and binocular treatment age, according to the types of treatment (Table 2). Five patients (22.7%) gained more than 0.2 LogMAR of vision (1 of 10 patients [10%] in

| Table 1 | Demographic and clinical characteristics in children with residual amblyopia following occlusion for more than 6 months |
|---------|-------------------------------------------------------------------------------------------------|
| Sex     | 15:7                                                                                           |
| Refractive error (diopters) |                                                                                               |
| Amblyopic eye | +3.16 ± 4.10 (range = −5.50~7.50)                                                              |
| Fellow eye | +2.31 ± 2.67 (range = −2.25~7.75)                                                               |
| Laterality of amblyopic eye (right:left) | 7:15                                                                                           |
| Types of amblyopia (A:S:C) | 7:8:7                                                                                          |
| VA at initial visit (LogMAR) | 0.73 ± 0.047 (range 0.2~1.8)                                                                   |
| Duration of occlusion (years) | 2.5 ± 1.1 (range 0.7~4.7)                                                                       |
| VA after occlusion (LogMAR) | 0.22 ± 0.20 (range 0.05~1.0)                                                                    |
| Age at binocular treatment (years) | 8.7 ± 1.3 (range 6.7~11.1)                                                                     |
| Stereoacuites at binocular treatment (Logarcsec) | 2.3 ± 0.2 (range 1.9~2.6)                                                                       |
| Duration of binocular treatment (months) | 4.4 ± 1.8 (range 2.1~8.1)                                                                       |
| VA after binocular treatment (LogMAR) | 0.18 ± 0.15 (range 0.0~0.5)                                                                    |

Continuous variables are reported as mean ± standard deviation
Abbreviations: A anisometropic, S strabismic, C combined, VA visual acuity, LogMAR logarithm of the minimum angle of resolution

Lee and Kim BMC Ophthalmology (2018) 18:253
the BF group, 2 of 7 patients [28.6%] in the HMD group, and 2 of 5 patients [40%] in the BF + HMD group, Fig. 2).

**Discussion**

Though the mainstay treatment for unilateral amblyopia has traditionally been penalization of the sound eye, there is growing interest in the role of binocular treatments. As further clinical evidence on amblyopia management is accumulated, there may be a shift from penalization and an inclination toward binocular stimulation to improve binocular interaction and promote binocularity.

Binocularity-stimulating treatments include the use of movies and video games displayed on a split screen, with some media components presented in low contrast images for the sound eye and high contrast images for the amblyopic eye. Li et al. [26] examined the effect of watching three dichoptic movies per week for 2 weeks on 8 amblyopic patients (4 patients with anisometropic amblyopia, 1 patient with strabismic amblyopia, and 4 patients with combination amblyopia) that were 4–10 years old. Before treatment, the amblyopic eye visual acuity ranged from 0.24–1.20 LogMAR. They reported that the mean improvement in visual acuity was 2 lines. However, their study only included a small number of patients and had a short follow-up period (2 weeks).

Vedamurthy et al. [27] conducted a larger study on older patients that compared amblyopic patients who watched movies with a patch (n = 15 patients) to those who played dichoptic video games (n = 23 patients). In each treatment group, approximately half of patients had anisometropic amblyopia and half of patients had strabismic amblyopia.

### Table 2

Comparison of clinical factors and visual acuity in children with residual amblyopia following occlusion for more than 6 months according to the treatment modalities

|                          | BF (n = 10) | HMD (n = 7) | BF + HMD (n = 5) | P value |
|--------------------------|------------|-------------|-----------------|---------|
| Sex (male:female)        | 6:4        | 5:2         | 4:1             | 0.852a  |
| Types of amblyopia (A:S:C)| 3:5:2      | 3:2:2       | 1:1:3           | 0.634b  |
| VA at initial visit (LogMAR) | 0.66 ± 0.44 | 0.77 ± 0.53 | 0.80 ± 0.58     | 0.844a  |
| Duration of occlusion (years) | 2.9 ± 1.3   | 2.6 ± 1.0   | 1.8 ± 0.5       | 0.215a  |
| VA after occlusion (LogMAR) | 0.17 ± 0.12 | 0.30 ± 0.32 | 0.21 ± 0.11     | 0.411a  |
| Age at binocular treatment (years) | 8.3 ± 1.2   | 8.7 ± 1.5   | 9.5 ± 1.4       | 0.289a  |
| Duration of binocular treatment (months) | 4.7 ± 2.4   | 4.2 ± 1.4   | 4.1 ± 1.1       | 0.795a  |
| VA after binocular treatment (LogMAR) | 0.19 ± 0.17 | 0.17 ± 0.07 | 0.17 ± 0.19     | 0.958a  |

Continuous variables are reported as mean ± standard deviation

Abbreviations: BF Bangerter foil, HMD Head-mounted display, A anisometropic, S strabismic, C combined, VA visual acuity, LogMAR logarithm of the minimum angle of resolution

aANOVA test  
bFisher’s exact test  

---

**Fig. 2** Distribution and change of visual acuity in children with residual amblyopia following occlusion for more than 6 months. Five patients (22.7%) presented more than 0.2 logMAR improvement of visual acuity: 1 of 10 patients (10%) in the BF group, 2 of 7 patients (28.6%) in the HMD group, and 2 of 5 patients (40%) in the BF + HMD group.
Participants were required to perform their assigned visual activities for 1.5–2 h at least 2–5 times per week for a total of 40 h. They found that the dichoptic video game group had an overall improvement in stereopsis and contrast sensitivity shortly after and 2 months after initiating the intervention.

These prior studies included patients with newly diagnosed amblyopia and treated patients with binocularity-stimulating therapies without any experience of conventional treatment (e.g., patching) [20, 23, 24, 26]. In contrast, our study included amblyopic children who had reached a treatment response plateau after a sufficiently long period of occlusion therapy (residual amblyopes). Residual amblyopia is generally considered to be an untreatable condition, and conventional therapies offer no options for further visual acuity improvements. Before binocular therapy, mean occlusion duration was 2.5 ± 1.1 years and occlusion compliance was good. Even though 86.4% of our patients gained at least 2 lines of vision with more than 6 months of patching, vision in the amblyopic eye had still not reached that of the sound eye. Therefore, different treatments were needed to further improve visual acuity.

We tried binocularity-stimulating treatment using BF and HMD games. Chen et al. [28] reported that BF can immediately reduce suppression and promote binocular summation for mid/low spatial frequencies in observers with amblyopia. In addition, we previously developed a new software program that directly targets binocular function with dichoptic presentation [25]. This program presents 3-D images in a virtual reality environment using an HMD. The system targets binocular function by presenting 3-D images on a split screen. In the virtual reality environment, image contrast and intensity can be independently adjusted for each eye and were increased in the amblyopic eye and decreased in the sound eye. Therefore, patients are forced to use both the sound and amblyopic eye to successfully play games or watch movies. In the present study, mean patient age at the time of binocular treatment was 8.7 ± 1.3 years and mean binocularity-stimulating treatment duration was 4.4 ± 1.8 months. All patients had good therapy compliance. Of the 22 patients included, 5 patients (22.7%) gained more than 0.2 logMAR of vision. Even though we only examined a small number of patients, this result could be meaningful because we only included residual amblyopes.

Our study had several limitations. First, the number of subjects was small and there was no control group which was observed without any treatment. We could not include the control subjects because of ethical issue. In addition, even if we assigned the treatment randomly by masked physician, participants and investigators were not blinded after treatment. To check the compliance and detect any complications/side effects following binocular treatment, we had to know the types of treatment. However, it would be the major limitation, so further blinded prospective research on a larger group of amblyopic children and adults is necessary to prove binocular treatment efficacy. Second, images presented by the HMD had a relatively low resolution. Therefore, display resolution improvements are needed. Investigations to determine optimum utilization in the clinic and at patient homes are also needed.

Conclusions
To the best of our knowledge, this is the first study to report results of binocularity-stimulating treatment in children with residual amblyopia. There may be some benefit of binocularity-stimulating treatments in residual amblyopic children. Therefore, binocularity-stimulating treatments should be considered in children with residual amblyopia following long-term occlusion therapy.

Abbreviations
BF: Bangerter foil; D: Diopters; HMD: Head-mounted display

Funding
This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MOE) (No. 2017R1D1A1B03032985).

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Authors’ contributions
Design of the study (SJK); Conduct of the study (HJL, SJK); Collection and management of data (HJL, SJK); Analysis and interpretation of data (HJL, SJK); Preparation, review, or approval of the manuscript (HJL, SJK). All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study received ethical approval from the Institutional Review Board of the Seoul National University Hospital. The Ethics Committee study protocol number was 1706–205-866 and the IRB granted a waiver of consent for this retrospective chart review study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Ophthalmology, Seoul National University College of Medicine, Seoul, South Korea. 2Seoul Artificial Eye Center, Seoul National University Hospital Clinical Research Institute, Seoul, South Korea. 3Department of Ophthalmology, Seoul National University Hospital, 101 Daehak-Ro, Jongno-Gu, Seoul 110-744, Republic of Korea.

Received: 23 April 2018 Accepted: 13 September 2018
Published online: 20 September 2018

References
1. Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children. Arch Ophthal. 2002;120(3):268–78.
2. Levartovsky S, Gottesman N, Shimshoni M, Oliver M. Factors affecting long-term results of successfully treated amblyopia: age at beginning of
1. Barnhardt CN, Birch EE, Donahue SP, Everett DF, et al. A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children. Ophthalmol. 2006;113(8):904–12.

2. Rutstein RP, Quinn GE, Crouch ER, Holmes JM, Hoover DL, Leske DA, et al. A randomized trial comparing Bangerter filters and patching for the treatment of moderate amblyopia in children. Ophthalmol. 2010;117(5):998–1004 e1006.

3. Scott WE, Dickey CF. Stability of visual acuity in amblyopic patients after visual maturity. Graefe’s Arch Clin Exp Ophthalmol. 1988;226(2):154–7.

4. Holmes JM, Beck RW, Kraker RT, Astle WF, Cole SR, Cotter SA, Donahue S, Everett DF, Hertle RW, et al. Risk of amblyopia recurrence after cessation of treatment. Journal of AAOPOS. 2004;8(5):420–8.

5. Wallace DK, Edwards AR, Cotter SA, Beck RW, Arnold RW, Astle WF, Barnhardt CN, Birch EE, Donahue SP, Everett DF, et al. A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children. Ophthalmol. 2006;113(8):904–12.

6. Knox PJ, Simmers AJ, Gray LS, Cleary M. An exploratory study: prolonged periods of binocular stimulation can provide an effective treatment for childhood amblyopia. Invest Ophthalmol Vis Sci. 2013;54(2):817–24.

7. Li J, Thompson B, Deng D, Chan LY, Yu M, Hess RF. Dichoptic training enables the adult amblyopic brain to learn. Current Bio. 2013;23(8):R308–9.

8. Hess RF, Mansouri B, Thompson B. A binocular approach to treating amblyopia: antisuppression therapy. Optometry Vis Sci. 2010;87(9):697–704.

9. Hess RF, Mansouri B, Thompson B. Restoration of binocular vision in amblyopia. Strabismus. 2011;19(3):110–8.

10. Hess RF, Thompson B. New insights into amblyopia: binocular therapy and noninvasive brain stimulation. Journal of AAOPOS. 2013;7(1):89–93.

11. Li RW, Young KG, Hoenig P, Levi DM. Perceptual learning improves visual performance in juvenile amblyopia. Invest Ophthalmol Vis Sci. 2005;46(9):3161–8.

12. Bossi M, Anderson EJ, Tailor V, Bex PJ, Greenwood JA, Dahlmann-Noor A, Dakin SC. An exploratory study of a novel home-based binocular therapy for childhood amblyopia. Investigative Ophthalmology and Visual Science. 2014;55:ARVO E-Abstract 5981.

13. Cooperstock J. An iPod treatment of amblyopia: an updated binocular approach. Optometry. 2012;83(2):87–94.

14. Li RW, Young KG, Hoenig P, Levi DM. Perceptual learning improves visual performance in juvenile amblyopia. Invest Ophthalmol Vis Sci. 2005;46(9):3161–8.

15. Bossi M, Anderson EJ, Tailor V, Bex PJ, Greenwood JA, Dahlmann-Noor A, Dakin SC. An exploratory study of a novel home-based binocular therapy for childhood amblyopia. Investigative Ophthalmology and Visual Science. 2014;55:ARVO E-Abstract 5981.

16. Herbison N, Cobb S, Gregson R, Ash I, Eastgate R, Purdy J, Hepburn T. Results of a pilot study of 3D shutter glasses system. Eye. 2013;27(9):1077–83.

17. Herbison N, Gregson R, Ash I, Eastgate R, Purdy J, Hepburn T. Evaluation and development of a novel binocular treatment (I-BIT) system using video clips and interactive games to improve vision in children with amblyopia (‘lazy eye’): study protocol for a randomised controlled trial. Trials. 2013;14:145.

18. Birch EE, Li SL, Jost RM, Morale SE, De La Cruz A, Stager D Jr, Diao L, Stager DR Sr. Binocular iPad treatment for amblyopia in preschool children. J AAOPOS. 2015;9(1):16–11.

19. Iida H, Ishikawa H, Shoji N, Ikeda T, Totuka S, Goseki T, Shimizu K. Modified iPad for treatment of amblyopia: a preliminary study. J AAOPOS. 2015;9(6):552–4.

20. Li SL, Jost RM, Morale SE, De La Cruz A, Diao L, Stager D Jr, Birch EE. Binocular iPad treatment of amblyopia for lasting improvement of visual acuity. JAMA Ophthalmology. 2015;133(4):479–80.

21. Li SL, Jost RM, Morale SE, Stager DR, Diao L, Stager D, Birch EE. A binocular iPad treatment for amblyopia in children. Eye. 2014;28(10):1246–53.

22. Kelly KR, Jost RM, Diao L, Beauchamp CL, Leffler JR, Birch EE. Binocular iPad game vs patching for treatment of amblyopia in children: a randomized clinical trial. JAMA Ophthalmology. 2016;134(12):1402–8.

23. Lee HJ, Kim S-J. Newly developed binocular treatment of amblyopia using head-mounted display. Invest Ophthalmol Vis Sci. 2016;57(12):3081–1.